1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

AM-Pharma Holding B.V.

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2000

Location

Utrecht Netherlands

Primary Industry

Biotechnology

About

Based in Bunnik, Netherlands, and founded in 2002 and led by Chief Executive Officer Juliane Bernholz, AM-Pharma B.V. operates as a biopharmaceuticals-based company providing therapeutics that treat acute kidney injury (AKI) and other inflammatory and infectious diseases. In July 2019, AM-Pharma B.V. raised EUR 116 million in venture funding led by LSP and Andera Partners, with participation from Forbion, Ysios Capital, Kurma Partners, ID Invest Partners and Gilde Healthcare, and BB Pureos Bioventures.
Current Investors
Idinvest Partners, Andera Partners, EQT Life Sciences

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.am-pharma.com
Company Stage
Series D
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo